Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Marmorino F, Rossini D, Lonardi S, Moretto R, Zucchelli G, Aprile G, Dell'Aquila E, Ratti M, Bergamo F, Masi G, Urbano F, Ronzoni M, Libertini M, Borelli B, Randon G, Buonadonna A, Allegrini G, Pella N, Ricci V, Boccaccino A, Latiano TP, Cordio S, Passardi A, Tamburini E, Boni L, Falcone A, Cremolini C. Marmorino F, et al. Among authors: pella n. Ann Oncol. 2019 Dec 1;30(12):1969-1977. doi: 10.1093/annonc/mdz403. Ann Oncol. 2019. PMID: 31573612 Free article. Clinical Trial.
Cisplatin and gemcitabine in non-small-cell lung cancer.
Cartei G, Sacco C, Sibau A, Pella N, Iop A, Tabaro G. Cartei G, et al. Among authors: pella n. Ann Oncol. 1999;10 Suppl 5:S57-62. doi: 10.1093/annonc/10.suppl_5.s57. Ann Oncol. 1999. PMID: 10582141 Free article. Review.
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G. Cecchin E, et al. Among authors: pella n. Pharmacogenomics J. 2013 Oct;13(5):403-9. doi: 10.1038/tpj.2012.31. Epub 2012 Aug 7. Pharmacogenomics J. 2013. PMID: 22868256 Free PMC article.
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.
Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G. Cecchin E, et al. Among authors: pella n. Pharmacogenomics J. 2015 Jun;15(3):219-25. doi: 10.1038/tpj.2014.64. Epub 2014 Oct 21. Pharmacogenomics J. 2015. PMID: 25331073
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.
Ruzzo A, Graziano F, Galli F, Giacomini E, Floriani I, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M. Ruzzo A, et al. Among authors: pella n. Sci Rep. 2014 Nov 5;4:6828. doi: 10.1038/srep06828. Sci Rep. 2014. PMID: 25370899 Free PMC article. Clinical Trial.
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
Foltran L, De Maglio G, Pella N, Ermacora P, Aprile G, Masiero E, Giovannoni M, Iaiza E, Cardellino GG, Lutrino SE, Mazzer M, Giangreco M, Pisa FE, Pizzolitto S, Fasola G. Foltran L, et al. Among authors: pella n. Future Oncol. 2015;11(4):629-40. doi: 10.2217/fon.14.279. Future Oncol. 2015. PMID: 25686118 Free article.
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, Miolo G, Mini E, Nobili S, Lonardi S, Pella N, Lo Re G, Montico M, Roncato R, Dreussi E, Gagno S, Cecchin E. Toffoli G, et al. Among authors: pella n. Int J Cancer. 2015 Dec 15;137(12):2971-80. doi: 10.1002/ijc.29654. Epub 2015 Jul 14. Int J Cancer. 2015. PMID: 26099996 Free article.
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.
Garziera M, Bidoli E, Cecchin E, Mini E, Nobili S, Lonardi S, Buonadonna A, Errante D, Pella N, D'Andrea M, De Marchi F, De Paoli A, Zanusso C, De Mattia E, Tassi R, Toffoli G. Garziera M, et al. Among authors: pella n. PLoS One. 2015 Dec 3;10(12):e0144000. doi: 10.1371/journal.pone.0144000. eCollection 2015. PLoS One. 2015. PMID: 26633805 Free PMC article.
68 results